Desley van Zoggel

PET/CT response after induction chemotherapy 137 CHAPTER 7 17. Gade M, Kubik M, Fisker R V., et al. Diagnostic value of 18F-FDG PET/CT as first choice in the detection of recurrent colorectal cancer due to rising CEA. Cancer Imaging. 2015;15:1–8. 18. Rymer B, Curtis NJ, Siddiqui MRS, et al. FDG PET/CT can assess the response of locally advanced rectal cancer to neoadjuvant chemoradiotherapy: Evidence from meta-analysis and systematic review. Clinical Nuclear Medicine. 2016;41:371–375. 19. Cerny M, Dunet V, Rebecchini C, et al. Response of locally advanced rectal cancer (LARC) to radiochemotherapy: DW-MRI and multiparametric PET/CT in correlation with histopathology. NuklearMedizin. 2019;58:28–38. 20. Maffione AM, Ferretti A, Grassetto G, et al. Fifteen different 18F-FDG PET/CT qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy. Eur J Nucl MedMol Imaging. 2013;40:853– 864. 21. Leccisotti L, Gambacorta MA, de Waure C, et al. The predictive value of 18F-FDG PET/CT for assessing pathological response and survival in locally advanced rectal cancer after neoadjuvant radiochemotherapy. Eur J Nucl Med Mol Imaging. 2015;42:657–666. 22. Avallone A, Aloj L, Pecori B, et al. 18F-FDG PET/CT is an early predictor of pathologic tumor response and survival after preoperative radiochemotherapywith bevacizumab in high-risk locally advanced rectal cancer. J Nucl Med. 2019;60:1560–1568. 23. Bang JI, Ha S, Kang SB, et al. Prediction of neoadjuvant radiation chemotherapy response and survival using pretreatment [18F]FDG PET/CT scans in locally advanced rectal cancer. Eur J Nucl Med Mol Imaging. 2016;43:422–431. 24. Giannini V, Mazzetti S, Bertotto I, et al. Predicting locally advanced rectal cancer response to neoadjuvant therapy with 18 F-FDG PET and MRI radiomics features. Eur J Nucl Med Mol Imaging. 2019;46:878–888. 25. Kawai K, Nozawa H, Hata K, et al. Optimal Interval for 18 F-FDG-PET After Chemoradiotherapy for Rectal Cancer. Clin Colorectal Cancer. 2018;17:e163–e170. 26. ChonHJ, KimC, Cho A, et al. The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer. Gastric Cancer. 2019;22:113–122. 27. Landis JR, Koch GG. The Measurement of Observer Agreement for Categorical Data. Biometrics. 1977;33:159.